LigaChem Biosciences Inc.
KOSDAQTotal Valuation
LigaChem Biosciences Inc. carries a market capitalization of 5.41T, placing it among publicly traded companies globally. Its enterprise value stands at 6.59T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.41T |
| Enterprise Value | 6.59T |
Share Statistics
LigaChem Biosciences Inc. currently has 36.41M shares outstanding.
| Shares Outstanding | 36.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
LigaChem Biosciences Inc. trades at a trailing price-to-earnings ratio of 1,784.94. The price-to-sales ratio is 55.47, and the price-to-book ratio stands at 36.38.
| PE Ratio | 1,784.94 |
| PS Ratio | 55.47 |
| PB Ratio | 36.38 |
| P/TBV Ratio | 17.63 |
| P/FCF Ratio | -51.98 |
| P/OCF Ratio | -49.69 |
Enterprise Valuation
The EV/Sales ratio of 52.39 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.67 provides insight into valuation relative to core operating earnings.
| EV / Sales | 52.39 |
| EV / EBITDA | 0.67 |
| EV / EBIT | 0.67 |
| EV / FCF | N/A |
Financial Position
LigaChem Biosciences Inc. maintains a current ratio of 10.12, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.52, indicating moderate leverage, while an interest coverage ratio of -97.27 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.12 |
| Quick Ratio | 9.03 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -97.27 |
Financial Efficiency
| Return on Equity (ROE) | -52.90 |
| Return on Assets (ROA) | -19.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 86.24 |
Taxes
| Income Tax | -3.31B |
| Effective Tax Rate | N/A |
Stock Price Statistics
LigaChem Biosciences Inc.'s stock has gained approximately 33.24373% over the past 52 weeks. The 50-day moving average sits at 183,460.00, while the 200-day moving average is 171,086.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | 33.24373% |
| 50-Day Moving Average | 183,460.00 |
| 200-Day Moving Average | 171,086.50 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, LigaChem Biosciences Inc. generated 125.87B in revenue and converted that into -138.08B in net income, yielding earnings per share of -4,161.47. EBITDA reached -155.28B, while operating income came in at -155.28B.
| Revenue | 125.87B |
| Gross Profit | 111.94B |
| Operating Income | -155.28B |
| Pretax Income | -154.64B |
| Net Income | -138.08B |
| EBITDA | -155.28B |
| EBIT | -155.28B |
| Earnings Per Share (EPS) | -4,161.47 |
Balance Sheet
LigaChem Biosciences Inc. holds 428.34B in cash and equivalents against 2.60B in total debt, resulting in a net debt position of -63.48B. Total book value stands at 191.94B, with working capital of 432.53B providing operational flexibility.
| Cash & Cash Equivalents | 428.34B |
| Total Debt | 2.60B |
| Net Debt | -63.48B |
| Equity (Book Value) | 191.94B |
| Book Value Per Share | 5,278.21 |
| Working Capital | 432.53B |
Cash Flow
LigaChem Biosciences Inc. produced -140.52B in operating cash flow over the past twelve months. After subtracting -6.18B in capital expenditures, free cash flow totaled -146.70B - equivalent to -4,034.12 per share.
| Operating Cash Flow | -140.52B |
| Capital Expenditures | -6.18B |
| Free Cash Flow | -146.70B |
| FCF Per Share | -4,034.12 |
Margins
LigaChem Biosciences Inc. operates with a gross margin of 88.94, reflecting its pricing power and cost economics. The operating margin of -123.37 and net profit margin of -109.71 provide insight into operational efficiency.
| Gross Margin | 88.94 |
| Operating Margin | -123.37 |
| Pretax Margin | -122.86 |
| Profit Margin | -109.71 |
| EBITDA Margin | -123.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.03 |
| FCF Yield | -1.92 |
Stock Splits
LigaChem Biosciences Inc.'s most recent stock split took place on June 16, 2020 with a 1:2 split ratio.
| Last Split Date | 6/16/2020 |
| Split Ratio | 1:2 |
Scores
LigaChem Biosciences Inc. posts an Altman Z-Score of 28.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 28.17 |